{"schema_version":"secwatch.filing_event.v1","accession":"0001785530-24-000018","form_type":"8-K","ticker":"HOWL","cik":"0001785530","company_name":"Werewolf Therapeutics, Inc.","filed_at":"2024-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.101358+00:00","generated_at":"2026-06-02T23:15:34.091195+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Werewolf Therapeutics reports Q1 net loss of $16.2M; cash runway extended to Q1 2026","bullets":["Net loss $16.2M in Q1 2024, up from $12.0M loss in Q1 2023; R&D expenses rose to $12.9M.","Cash and equivalents $139.2M at March 31, 2024; new $60M loan from K2 HealthVentures ($30M drawn) extends runway through Q1 2026.","Collaboration revenue from Jazz Pharma fell to $0.7M from $4.5M YoY.","Planned ASCO 2024 presentation of WTX-124 combination dose-escalation data; Q2 interim data for WTX-330 monotherapy.","Preclinical advances: WTX-518 and WTX-712 show tumor regressions in mouse models; IL-10 for IBD presented at AAI."],"urls":{"canonical":"https://secwatch.observer/filing/0001785530-24-000018","json":"https://secwatch.observer/filing/0001785530-24-000018.json","markdown":"https://secwatch.observer/filing/0001785530-24-000018.md","text":"https://secwatch.observer/filing/0001785530-24-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785530/000178553024000018/0001785530-24-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785530/000178553024000018/howl-20240503.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T23:15:34.091195+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"590ced8a5464f1ccedae09cd92d509b2e8ad8e7c","claim":"Werewolf Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $0.7 million.","evidence_excerpt":"be sufficient to fund operational expenses and capital expenditure requirements through at least the first quarter of 2026. • Collaboration revenue: Collaboration revenue was $0.7 million for the first quarter of 2024, compared to $4.5 million for the same period in 2023. Collaboration revenue consists of revenue recognized from the Company’s licensing agreement","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1785530/000178553024000018/0001785530-24-000018-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$0.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}